Boy’s £1.8m drug treatment gives him new lease of life
▼ Summary
– Edward, a five-year-old with spinal muscular atrophy (SMA), received the one-off gene therapy Zolgensma through the NHS, which is considered the world’s most expensive drug.
– The treatment has enabled Edward to walk independently and achieve milestones like swimming and starting school, which his family once thought impossible.
– His progress is also attributed to extensive private physiotherapy funded by a £170,000 fundraising campaign, as the family moved to London for his care.
– Zolgensma offers a one-time injection alternative to lifelong treatments like Spinraza, and over 150 children in England have benefited from it through the NHS.
– Medical professionals are optimistic that such gene therapies will make more conditions treatable, though long-term outcomes for Zolgensma are still being studied.
A five-year-old boy from Colchester has achieved remarkable milestones after receiving a groundbreaking gene therapy, considered the world’s most expensive drug, through the NHS. Edward, who lives with spinal muscular atrophy (SMA), can now walk independently and is described by his mother as full of life and joy. This one-time treatment, called Zolgensma, has fundamentally altered his prognosis and daily reality.
Spinal muscular atrophy is a genetic condition that affects about 65 newborns in England each year. It leads to severe muscle weakness, impacting movement and breathing. Without medical intervention, most children with the most severe form do not survive beyond two years of age. Edward was diagnosed at just two months old. His mother, Megan, recalls the uncertainty they faced, never knowing what quality of life her son might have.
Before receiving Zolgensma, Edward was on a different medication called Spinraza, which requires lifelong regular spinal injections. In 2021, he became one of the first children in England to get the one-off gene therapy infusion. While the publicly listed price is £1.79 million, NHS England secured a confidential discount. The treatment works by addressing the root genetic cause, providing the body with a functioning copy of the gene that produces a protein essential for muscle development.
The results have been transformative. “He is my pride and joy,” Megan said. From a lethargic baby, Edward has grown into a cheeky and playful boy. He recently underwent a double hip replacement and is back on his feet, managing to walk 20 to 30 steps on his own. This summer, he jumped off a boat into the sea and rode a jet ski. He has also learned to swim and float independently, a significant challenge for children with SMA due to their lack of natural buoyancy.
Edward has just started school, where he has made many friends and participates in activities like any other five-year-old. His progress has drawn attention from medical professionals, who often visit him in hospital just to witness firsthand the impact of the therapy. “They want to see what gene therapy has done for him,” his mother noted.
To support his ongoing development, the family relocated to London so Edward can access intensive physiotherapy up to five times a week. Megan left her career in event management to care for him full-time. Initially uncertain if he would qualify for the NHS treatment, she launched a fundraising campaign that gathered £170,000 over five years. These funds have been crucial, covering private physiotherapy and specialist equipment that Megan credits for his continued improvement. “It has saved us as a family, not having to worry about the money,” she said, though the funds are now nearly depleted, prompting a new fundraising effort.
While long-term outcomes for Zolgensma are still being studied because it is a relatively new drug, Megan is hopeful. She believes this generation of children with SMA could be the first to commonly reach adulthood thanks to such advances. Professor James Palmer, NHS England’s medical director for specialised commissioning, echoed this optimism. He stated it was a pleasure to see the remarkable benefits for Edward and over 150 other children treated so far, expressing confidence that more conditions will become treatable as medical science progresses rapidly.
Edward may use a wheelchair at times in the future, but for his family, that is secondary. “It does not matter, as long as he is happy,” Megan said. “We are so proud of him.” His story highlights the profound impact of medical innovation and the vital role of both public healthcare systems and community support in changing lives.
(Source: BBC)
